Alzheimer Disease

Leqembi is an intravenous injection for the treatment of Alzheimer disease.

Brexpiprazole was associated with a statistically and clinically meaningful improvement in agitative behaviors caused by dementia compared to placebo.

Lack of awareness, or anosognosia, may be present up to 2 to 3 years before an Alzheimer dementia diagnosis is made.

More than half of patients with Alzheimer disease administered donanemab showed a significantly reduced cognitive and functional decline.

As more drugs gain coverage, decision-makers will need to more accurately diagnose Alzheimer disease, especially in the community setting.

Strong interprofessional team helps ensure safe transitions and minimize adverse events, medication errors

Perceived stress and cognitive performance are independently associated. Stress can also increase the risk of worsening cognition.

Eli Lilly treatment targets soluble amyloid beta and did not clear plaque or halt accumulation of amyloid in individuals treated with the drug in the A4 study.

Investigators noted medication prescription disparities among patients with dementia despite factoring for age and sex.

Low cognitive functioning and cognitive decline have been linked to an increased risk of morbidity and mortality.

Promising results for lecanemab's efficacy in patients with mild cognitive impairment or mild dementia associated with Alzheimer disease were accompanied by reports of adverse effects associated with treatment.

The model can predict the chronological ages of cognitively normal participants with an average absolute error of 2.3 years, which is about 1 year more accurate than an existing model.

The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.

Lecanemab (Lequembi) approved to treat mild cognitive impairment or mild dementia associated with Alzheimer disease.

Indication can play a major role in pharmacists recommending brain health products.

White adults in their midlife showed slower brain aging than Black and Latinx individuals, but between mid- and late life, they showed increased signs of aging.

Legislation expands protection of original 1965 act to individuals younger than 60 years.

Patients with Alzheimer disease administered gantenerumab did experience slower clinical decline, however, it was not deemed statistically significant.

Eisai plans to file for traditional approval in the United States by March 31, 2023.

Tacrine was originally brought to the market in 1993 as an acetylcholinesterase inhibitor to fight the symptoms of Alzheimer disease.

Patients with type 2 diabetes may lower their risk of developing severe neurological disorders like Alzheimer disease by taking certain anti-diabetic medications alongside daily insulin.

New research about the risks of dementia in patients with non-affective psychotic disorders could help shape new life course models for prevention.

Antioxidants are capable of converting highly destructive free radicals and nonradical molecules, thereby reducing cerebral stress.

The history of targeting neuroinflammation is a good example of the challenges to finding a treatment for Alzheimer disease.

In a study of 2262 individuals, investigators also found that cocoa extract had no effect on cognition.

A recent study revealed that social activities like gardening or getting a college degree could improve cognition in older age, which could possibly prevent Alzheimer disease.

Data indicate that consumption of 7 or more units of alcohol per week is associated with higher iron levels in the brain, which has been linked to Alzheimer and Parkinson diseases.

Brexpiprazole is indicated as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

Statistics indicate possible benefit of home-based palliative care interventions, according to study results from the Indiana University School of Medicine and the Regenstrief Institute.

Conditions such as high blood pressure, diabetes, and obesity may have a significant impact on the likelihood of developing cognitive decline, dementia, and Alzheimer disease.